Biomerica rises on seeking FDA approval for bacterial infection test

Biomerica

26/04/2022 16:05

** Shares of diagnostic co  BMRA.O  rise 2.8% to $4.17
    ** Co says it has submitted a marketing application with the
U.S. FDA for its test to detect H. pylori infection  urn:newsml:reuters.com:*:nGNX1pZNwx
    ** H. pylori infection is a bacterial infection that causes
stomach inflammation (gastritis), peptic ulcer disease, and
certain types of stomach cancer
    ** FDA's goal is to provide a decision within 90 days to the
submitting company, unless further information is requested
    ** Biomerica is also preparing to submit a CE Mark filing,
which will enable the product to be sold in most EU countries
    ** Stock up ~7.4% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))